GlassScriptPhysician profile
Daniel M Anderson
NPI 1285216366
$731.78
in general payments reported to CMS, 2019-2025
18 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $159 · 2024: $310 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $178.51 | 2024-2025 | Evenity, Otezla, Repatha |
| Shionogi INC | $124.98 | 2023 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $67.18 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $48.30 | 2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $41.13 | 2024-2025 | Inspire |
| Merck Sharp & Dohme LLC | $35.14 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi-Aventis U.S. LLC | $30.67 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.18 | 2024 | Synjardy, Jardiance |
| Dynavax Technologies Corporation | $23.79 | 2024 | Heplisav-B |
| Dexcom, INC. | $22.15 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $21.24 | 2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $18.92 | 2024 | Spravato |
| Glaxosmithkline, LLC. | $17.95 | 2024 | Bexsero |
| Abbvie INC. | $17.94 | 2023 | Liletta |
| Janssen Biotech, INC. | $15.80 | 2023 | Darzalex, Tecvayli |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $15.50 | 2025 | |
| Astellas Pharma US INC | $14.30 | 2024 | Veozah |
| Becton, Dickinson and Company | $14.10 | 2025 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.